Breakthrough in TB Treatment: Introducing Sutezolid & Delpazolid

Recent Phase 2b trials in South Africa and Tanzania have revealed two novel oxazolidinone antibiotics—sutezolid and delpazolid—with potent activity against tuberculosis and notably fewer side effects than linezolid, the current regimen for drug-resistant TB 1.

Why Linezolid Needs a Replacement

Since 2022, linezolid has been a cornerstone in the six-month BPaLM regimen (bedaquiline, pretomanid, linezolid, moxifloxacin). Though effective, extended linezolid use often leads to severe adverse effects like anemia and optic neuropathy, prompting treatment discontinuation 2.

Clinical Trials: Design & Findings

Two international multicenter trials—PanACEA-SUDOCU‑01 and PanACEA-DECODE‑01—enrolled ~150 adults with drug-sensitive pulmonary TB. Participants received either sutezolid or delpazolid along with bedaquiline, delamanid, and moxifloxacin over 16 weeks 3.

• Sutezolid (PanACEA‑SUDOCU‑01): Across multiple doses, strong bactericidal effects were seen—only two mild drug-related adverse events and no anemia, neuropathy, or lactic acidosis 4.
• Delpazolid (PanACEA‑DECODE‑01): 1,200 mg doses enhanced microbial clearance with only one minor adverse event, and no serious toxicity reported 5.

Expert Opinions

Dr Norbert Heinrich (LMU Munich) highlighted the urgent need for safer linezolid alternatives. Dr Ivan Norena noted that fewer side effects could improve adherence and outcomes. Dr Tina Minja emphasized these drugs’ potential for longer TB therapies 6.

Implications for Global TB Care

With over 10 million TB cases and nearly 500,000 drug-resistant TB cases globally in 2022, safer regimens are vital—especially in regions like Africa where resistance is high 7. These new drugs may reduce treatment interruptions and improve cure rates.

Next Steps: Phase 3 Trials and Wider Adoption

While findings are promising, larger Phase 3 trials—including patients with HIV and diverse populations—are needed. If successful, sutezolid and delpazolid could soon supplant linezolid in MDR‑TB regimens.

Trivia & Quiz Facts

• Linezolid was first approved in 2022 as part of WHO’s six-month MDR-TB BPaLM regimen.
• The term oxazolidinones refers to the class of antibiotics including linezolid, sutezolid, and delpazolid.
• TB is one of the top 10 global causes of death; drug-resistant TB complicates treatment.
• Phase 2b trials typically assess safety and preliminary efficacy in ~100–200 participants.

Conclusion

The development of sutezolid and delpazolid marks a promising leap in TB treatment—offering potent bacterial clearance with significantly fewer side effects. These antiv microbials may soon change the landscape of drug-resistant TB care.

Source: Mid-day